What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?
Understanding the molecular causes and finding appropriate therapies for psychiatric disorders are challenging tasks for research; -omics technologies are used to elucidate the molecular mechanisms underlying brain dysfunction in a hypothesis-free manner. In this review, we will focus on mass spectrometry-based proteomics and metabolomics and address how these approaches have contributed to our understanding of psychiatric disorders. Specifically, we will discuss what we have learned from mass spectrometry-based proteomics and metabolomics studies in rodent models and human cohorts, outline current limitations and discuss the potential of these methods for future applications in psychiatry.
Max Planck Institute of Psychiatry, Munich, Germany.
Christoph W
CW
Turck
Max Planck Institute of Psychiatry, Munich, Germany.
Michaela D
MD
Filiou
Biomarkers; Diagnostics; Mass spectrometry; Metabolomics; Molecular signatures; Proteomics; Psychiatric disorders